Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.75
NAS:MYGN's Cash to Debt is ranked lower than
65% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. NAS:MYGN: 0.75 )
Ranked among companies with meaningful Cash to Debt only.
NAS:MYGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.75  Med: No Debt Max: No Debt
Current: 0.75
Equity to Asset 0.58
NAS:MYGN's Equity to Asset is ranked lower than
53% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:MYGN: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NAS:MYGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.58  Med: 0.9 Max: 0.96
Current: 0.58
0.58
0.96
Interest Coverage No Debt
NAS:MYGN's Interest Coverage is ranked higher than
98% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NAS:MYGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:MYGN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 7
Z-Score: 2.16
M-Score: -2.95
WACC vs ROIC
2.24%
15.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 17.33
NAS:MYGN's Operating margin (%) is ranked higher than
86% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. NAS:MYGN: 17.33 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:MYGN' s Operating margin (%) Range Over the Past 10 Years
Min: -30.37  Med: 35.81 Max: 39.24
Current: 17.33
-30.37
39.24
Net-margin (%) 13.03
NAS:MYGN's Net-margin (%) is ranked higher than
87% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. NAS:MYGN: 13.03 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:MYGN' s Net-margin (%) Range Over the Past 10 Years
Min: -22.25  Med: 22.63 Max: 42
Current: 13.03
-22.25
42
ROE (%) 13.12
NAS:MYGN's ROE (%) is ranked higher than
79% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. NAS:MYGN: 13.12 )
Ranked among companies with meaningful ROE (%) only.
NAS:MYGN' s ROE (%) Range Over the Past 10 Years
Min: -11.85  Med: 18.28 Max: 30.71
Current: 13.12
-11.85
30.71
ROA (%) 10.41
NAS:MYGN's ROA (%) is ranked higher than
87% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. NAS:MYGN: 10.41 )
Ranked among companies with meaningful ROA (%) only.
NAS:MYGN' s ROA (%) Range Over the Past 10 Years
Min: -10.72  Med: 16.98 Max: 28.73
Current: 10.41
-10.72
28.73
ROC (Joel Greenblatt) (%) 85.66
NAS:MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. NAS:MYGN: 85.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:MYGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -199.02  Med: 251.31 Max: 362.64
Current: 85.66
-199.02
362.64
Revenue Growth (3Y)(%) 11.70
NAS:MYGN's Revenue Growth (3Y)(%) is ranked higher than
75% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. NAS:MYGN: 11.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:MYGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.6  Med: 20.1 Max: 31.4
Current: 11.7
1.6
31.4
EBITDA Growth (3Y)(%) -2.50
NAS:MYGN's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NAS:MYGN: -2.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:MYGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 12.15 Max: 48.5
Current: -2.5
-10.2
48.5
EPS Growth (3Y)(%) -1.10
NAS:MYGN's EPS Growth (3Y)(%) is ranked higher than
53% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. NAS:MYGN: -1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:MYGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17  Med: 3.3 Max: 67.9
Current: -1.1
-17
67.9
» NAS:MYGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MYGN Guru Trades in Q4 2015

Joel Greenblatt 196,364 sh (New)
RS Investment Management 1,998,910 sh (New)
Paul Tudor Jones 21,386 sh (+89.69%)
Jim Simons 949,600 sh (+10.86%)
Ken Fisher 89,775 sh (unchged)
Mario Gabelli 25,000 sh (unchged)
Chuck Royce 1,414,898 sh (-37.72%)
» More
Q1 2016

MYGN Guru Trades in Q1 2016

RS Investment Management 2,178,740 sh (+9.00%)
Jim Simons 1,034,800 sh (+8.97%)
Paul Tudor Jones 22,391 sh (+4.70%)
Joel Greenblatt 201,527 sh (+2.63%)
Ken Fisher 89,783 sh (+0.01%)
Mario Gabelli 25,000 sh (unchged)
Chuck Royce 1,284,698 sh (-9.20%)
» More
Q2 2016

MYGN Guru Trades in Q2 2016

Lee Ainslie 93,870 sh (New)
First Eagle Investment 368,980 sh (New)
Joel Greenblatt 360,830 sh (+79.05%)
Jim Simons 1,332,300 sh (+28.75%)
Ken Fisher 92,236 sh (+2.73%)
Mario Gabelli 25,000 sh (unchged)
RS Investment Management Sold Out
Chuck Royce 937,498 sh (-27.03%)
Paul Tudor Jones 14,167 sh (-36.73%)
» More
Q3 2016

MYGN Guru Trades in Q3 2016

Ron Baron 40,000 sh (New)
Paul Tudor Jones 31,742 sh (+124.06%)
Jim Simons 2,931,674 sh (+120.05%)
Lee Ainslie 152,050 sh (+61.98%)
Joel Greenblatt 421,728 sh (+16.88%)
Ken Fisher 92,381 sh (+0.16%)
First Eagle Investment Sold Out
Mario Gabelli Sold Out
Chuck Royce 90,369 sh (-90.36%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:ABAX, NAS:ALOG, NAS:KANG, NAS:AXDX, NAS:GHDX, NAS:MEDP, NAS:FMI, NAS:QDEL, NAS:NEO, NAS:VIVO, NYSE:ARA, NAS:EXAS, NAS:NTRA, NAS:BEAT, NAS:NRCIA, NAS:NVDQ, NAS:HSKA, NAS:LNTH, NAS:ONVO, NAS:SRDX » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Company's business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.

Ratios

vs
industry
vs
history
P/E(ttm) 12.85
MYGN's P/E(ttm) is ranked higher than
87% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. MYGN: 12.85 )
Ranked among companies with meaningful P/E(ttm) only.
MYGN' s P/E(ttm) Range Over the Past 10 Years
Min: 9.06  Med: 19.3 Max: 63.15
Current: 12.85
9.06
63.15
Forward P/E 16.03
MYGN's Forward P/E is ranked higher than
77% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.19 vs. MYGN: 16.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 12.85
MYGN's PE(NRI) is ranked higher than
87% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. MYGN: 12.85 )
Ranked among companies with meaningful PE(NRI) only.
MYGN' s PE(NRI) Range Over the Past 10 Years
Min: 9.06  Med: 18.45 Max: 40.65
Current: 12.85
9.06
40.65
Price/Owner Earnings (ttm) 18.21
MYGN's Price/Owner Earnings (ttm) is ranked higher than
74% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.10 vs. MYGN: 18.21 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.71  Med: 22.79 Max: 113.28
Current: 18.21
9.71
113.28
P/B 1.56
MYGN's P/B is ranked higher than
82% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. MYGN: 1.56 )
Ranked among companies with meaningful P/B only.
MYGN' s P/B Range Over the Past 10 Years
Min: 1.53  Med: 3.69 Max: 8.23
Current: 1.56
1.53
8.23
P/S 1.63
MYGN's P/S is ranked higher than
73% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. MYGN: 1.63 )
Ranked among companies with meaningful P/S only.
MYGN' s P/S Range Over the Past 10 Years
Min: 1.6  Med: 4.74 Max: 14.31
Current: 1.63
1.6
14.31
PFCF 9.77
MYGN's PFCF is ranked higher than
87% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.06 vs. MYGN: 9.77 )
Ranked among companies with meaningful PFCF only.
MYGN' s PFCF Range Over the Past 10 Years
Min: 7.62  Med: 16.87 Max: 142.72
Current: 9.77
7.62
142.72
POCF 9.37
MYGN's POCF is ranked higher than
79% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. MYGN: 9.37 )
Ranked among companies with meaningful POCF only.
MYGN' s POCF Range Over the Past 10 Years
Min: 7.22  Med: 15.76 Max: 43.64
Current: 9.37
7.22
43.64
EV-to-EBIT 9.35
MYGN's EV-to-EBIT is ranked higher than
87% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. MYGN: 9.35 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.5  Med: 10 Max: 44
Current: 9.35
-102.5
44
EV-to-EBITDA 7.65
MYGN's EV-to-EBITDA is ranked higher than
88% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. MYGN: 7.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.3  Med: 9.4 Max: 38.5
Current: 7.65
-161.3
38.5
PEG 2.05
MYGN's PEG is ranked higher than
68% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. MYGN: 2.05 )
Ranked among companies with meaningful PEG only.
MYGN' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.13 Max: 5.84
Current: 2.05
0.47
5.84
Shiller P/E 13.52
MYGN's Shiller P/E is ranked higher than
90% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.25 vs. MYGN: 13.52 )
Ranked among companies with meaningful Shiller P/E only.
MYGN' s Shiller P/E Range Over the Past 10 Years
Min: 13.08  Med: 48.27 Max: 2553
Current: 13.52
13.08
2553
Current Ratio 1.17
MYGN's Current Ratio is ranked lower than
83% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. MYGN: 1.17 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s Current Ratio Range Over the Past 10 Years
Min: 1.17  Med: 5.96 Max: 20.28
Current: 1.17
1.17
20.28
Quick Ratio 0.98
MYGN's Quick Ratio is ranked lower than
82% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. MYGN: 0.98 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 5.96 Max: 20.28
Current: 0.98
0.98
20.28
Days Inventory 82.13
MYGN's Days Inventory is ranked higher than
51% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. MYGN: 82.13 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s Days Inventory Range Over the Past 10 Years
Min: 22.14  Med: 48.49 Max: 82.13
Current: 82.13
22.14
82.13
Days Sales Outstanding 47.94
MYGN's Days Sales Outstanding is ranked higher than
71% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. MYGN: 47.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.41  Med: 46.88 Max: 72.25
Current: 47.94
38.41
72.25
Days Payable 45.17
MYGN's Days Payable is ranked lower than
61% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. MYGN: 45.17 )
Ranked among companies with meaningful Days Payable only.
MYGN' s Days Payable Range Over the Past 10 Years
Min: 45.17  Med: 80.13 Max: 280.85
Current: 45.17
45.17
280.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.00
MYGN's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. MYGN: 5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -6.5 Max: 5.9
Current: 5
-13.6
5.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.44
MYGN's Price/Projected FCF is ranked higher than
97% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. MYGN: 0.44 )
Ranked among companies with meaningful Price/Projected FCF only.
MYGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.44  Med: 1.13 Max: 20.87
Current: 0.44
0.44
20.87
Price/Median PS Value 0.35
MYGN's Price/Median PS Value is ranked higher than
86% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. MYGN: 0.35 )
Ranked among companies with meaningful Price/Median PS Value only.
MYGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 1.39 Max: 9.53
Current: 0.35
0.34
9.53
Earnings Yield (Greenblatt) (%) 10.69
MYGN's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. MYGN: 10.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 8.9 Max: 22.7
Current: 10.69
2.3
22.7
Forward Rate of Return (Yacktman) (%) 13.47
MYGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. MYGN: 13.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -19.9  Med: 3.8 Max: 29.4
Current: 13.47
-19.9
29.4

More Statistics

Revenue (TTM) (Mil) $747.7
EPS (TTM) $ 1.32
Beta-0.02
Short Percentage of Float46.38%
52-Week Range $15.92 - 44.57
Shares Outstanding (Mil)68.42

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 751 779 828
EPS ($) 0.98 1.22 1.34
EPS w/o NRI ($) 0.98 1.22 1.34
EPS Growth Rate
(3Y to 5Y Estimate)
-1.10%
Dividends Per Share ($)
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
MYRIAD GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Dec 02 2016
Has the Smart Money Unearthed a Hidden Gem in Myriad Genetics, Inc. (MYGN)? Dec 01 2016
Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS Nov 28 2016
How This Fund’s Investments in NorthStar Asset Management (NSAM), CONMED Corporation (CNMD) &... Nov 18 2016
MYRIAD GENETICS INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets,... Nov 14 2016
Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American... Nov 12 2016
MYRIAD GENETICS INC Financials Nov 09 2016
Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx® Nov 07 2016
Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx® Nov 07 2016
The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with... Nov 04 2016
The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with... Nov 04 2016
Myriad Posts 1Q Loss Vs Profit a Year Ago (MYGN) Nov 03 2016
MYRIAD GENETICS INC Files SEC form 10-Q, Quarterly Report Nov 02 2016
Myriad Genetics (MYGN) Earnings Miss, Revenues Top in Q1 Nov 02 2016
Edited Transcript of MYGN earnings conference call or presentation 1-Nov-16 8:30pm GMT Nov 01 2016
Myriad reports 1Q loss Nov 01 2016
Myriad reports 1Q loss Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)